159 related articles for article (PubMed ID: 20217513)
41. Vildagliptin selectively ameliorates GLP-1, GLUT4, SREBP-1c mRNA levels and stimulates β-cell proliferation resulting in improved glucose homeostasis in rats with streptozotocin-induced diabetes.
Akarte AS; Srinivasan BP; Gandhi S
J Diabetes Complications; 2012; 26(4):266-74. PubMed ID: 22626875
[TBL] [Abstract][Full Text] [Related]
42. Glucagon-Like Peptide 1 Analogs and their Effects on Pancreatic Islets.
Tudurí E; López M; Diéguez C; Nadal A; Nogueiras R
Trends Endocrinol Metab; 2016 May; 27(5):304-318. PubMed ID: 27062006
[TBL] [Abstract][Full Text] [Related]
43. Newly approved and promising antidiabetic agents.
Combettes M; Kargar C
Therapie; 2007; 62(4):293-310. PubMed ID: 17983555
[TBL] [Abstract][Full Text] [Related]
44. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
Morales J
Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
[TBL] [Abstract][Full Text] [Related]
45. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
Halimi S
Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591
[TBL] [Abstract][Full Text] [Related]
46. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
Montanya E; Sesti G
Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994
[TBL] [Abstract][Full Text] [Related]
47. Advances in the treatment of type 2 diabetes mellitus.
Israili ZH
Am J Ther; 2011; 18(2):117-52. PubMed ID: 19834322
[TBL] [Abstract][Full Text] [Related]
48. Glucagon-like peptide-1: modulator of β-cell dysfunction and death.
Rondas D; D'Hertog W; Overbergh L; Mathieu C
Diabetes Obes Metab; 2013 Sep; 15 Suppl 3():185-92. PubMed ID: 24003936
[TBL] [Abstract][Full Text] [Related]
49. The development of non-peptide glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes.
Moon HS; Kim MK; Son MH
Arch Pharm Res; 2011 Jul; 34(7):1041-3. PubMed ID: 21811909
[TBL] [Abstract][Full Text] [Related]
50. Function of a long-term, GLP-1-treated, insulin-secreting cell line is improved by preventing DPP IV-mediated degradation of GLP-1.
Green BD; Liu HK; McCluskey JT; Duffy NA; O'Harte FP; McClenaghan NH; Flatt PR
Diabetes Obes Metab; 2005 Sep; 7(5):563-9. PubMed ID: 16050949
[TBL] [Abstract][Full Text] [Related]
51. Second line therapy: type 2 diabetic subjects failing on metformin GLP-1/DPP-IV inhibitors versus sulphonylurea/insulin: for GLP-1/DPP-IV inhibitors.
Kumar A
Diabetes Metab Res Rev; 2012 Dec; 28 Suppl 2():21-5. PubMed ID: 23280862
[TBL] [Abstract][Full Text] [Related]
52. Medicinal Chemistry and Applications of Incretins and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus.
Lotfy M; Singh J; Kalász H; Tekes K; Adeghate E
Open Med Chem J; 2011; 5(Suppl 2):82-92. PubMed ID: 21966329
[TBL] [Abstract][Full Text] [Related]
53. New therapeutic strategies for the treatment of type 2 diabetes mellitus based on incretins.
Gallwitz B
Rev Diabet Stud; 2005; 2(2):61-9. PubMed ID: 17491680
[TBL] [Abstract][Full Text] [Related]
54. The glucagon-like peptide-1 analogue liraglutide promotes autophagy through the modulation of 5'-AMP-activated protein kinase in INS-1 β-cells under high glucose conditions.
Miao X; Gu Z; Liu Y; Jin M; Lu Y; Gong Y; Li L; Li C
Peptides; 2018 Feb; 100():127-139. PubMed ID: 28712893
[TBL] [Abstract][Full Text] [Related]
55. GLP-1-related proteins attenuate the effects of mitochondrial membrane damage in pancreatic β cells.
Ogata M; Iwasaki N; Ide R; Takizawa M; Uchigata Y
Biochem Biophys Res Commun; 2014 Apr; 447(1):133-8. PubMed ID: 24709081
[TBL] [Abstract][Full Text] [Related]
56. Glucagon-Like Peptide-1 Receptor Agonists: Beta-Cell Protection or Exhaustion?
van Raalte DH; Verchere CB
Trends Endocrinol Metab; 2016 Jul; 27(7):442-445. PubMed ID: 27160799
[TBL] [Abstract][Full Text] [Related]
57. Brain GLP-1 and insulin sensitivity.
Sandoval D; Sisley SR
Mol Cell Endocrinol; 2015 Dec; 418 Pt 1():27-32. PubMed ID: 25724479
[TBL] [Abstract][Full Text] [Related]
58. Glucagon-like peptide-1 (GLP-1) analogs: recent advances, new possibilities, and therapeutic implications.
Manandhar B; Ahn JM
J Med Chem; 2015 Feb; 58(3):1020-37. PubMed ID: 25349901
[TBL] [Abstract][Full Text] [Related]
59. GLP-1, a powerful physiological incretin: an update.
Malik J; Roohi N
J Biol Regul Homeost Agents; 2018; 32(5):1171-1176. PubMed ID: 30334409
[TBL] [Abstract][Full Text] [Related]
60. Liraglutide, the once-daily human GLP-1 analog, in the treatment of Type 2 diabetes.
Hribal ML; Sesti G
Expert Rev Endocrinol Metab; 2010 Jul; 5(4):495-505. PubMed ID: 30780808
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
